{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:12:10Z","timestamp":1791216730907,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.autrev.2017.02.008","type":"journal-article","created":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T16:01:59Z","timestamp":1487001719000},"page":"377-384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature"],"prefix":"10.1016","volume":"16","author":[{"given":"S\u00e9bastien","family":"Sanges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Rivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e8ne","family":"Mekinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Le Quellec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Chatelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Lescoat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Jego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Cazalets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Qu\u00e9m\u00e9neur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Le Gouellec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Senet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Franc\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Deroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Imbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latifatou","family":"Boukari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sen\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Deligny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Mathian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Agard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Pugnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Speca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Dubucquoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Hatron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2017.02.008_bb0005","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12016-010-8198-y","article-title":"Diagnosis and classification of systemic sclerosis","volume":"40","author":"Hachulla","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.autrev.2016.01.007","article-title":"Systemic sclerosis: an update in 2016","volume":"15","author":"Desbois","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.02.008_bb0015","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.autrev.2015.07.012","article-title":"Quality of life in systemic sclerosis","volume":"14","author":"Almeida","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.02.008_bb0020","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1568-9972(03)00004-1","article-title":"New insights into the pathogenesis of systemic sclerosis","volume":"2","author":"Tamby","year":"2003","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.02.008_bb0025","article-title":"Role of B cells in the pathogenesis of systemic sclerosis","author":"Sanges","year":"2016","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.autrev.2017.02.008_bb0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11926-015-0560-x","article-title":"Current approaches to the treatment of systemic-sclerosis-associated pulmonary arterial hypertension (SSc-PAH)","volume":"18","author":"Sobanski","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2017.02.008_bb0035","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.autrev.2005.09.003","article-title":"Targeted therapy for systemic sclerosis","volume":"5","author":"Steen","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.02.008_bb0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.autrev.2010.09.015","article-title":"Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy","volume":"10","author":"Wei","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.02.008_bb0045","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1136\/ard.61.3.277-a","article-title":"Home sequential high dose intravenous immunoglobulins in systemic autoimmune disease","volume":"61","author":"Hachulla","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.02.008_bb0050","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12016-009-8155-9","article-title":"Evidence for the use of intravenous immunoglobulins\u2014a review of the literature","volume":"38","author":"Kivity","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0055","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","article-title":"Safety of intravenous immunoglobulin (IVIG) therapy","volume":"6","author":"Katz","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.02.008_bb0060","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0065","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1385\/CRIAI:29:3:321","article-title":"Intravenous immunoglobulin and fibrosis","volume":"29","author":"Molina","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0070","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12026-014-8615-z","article-title":"Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future","volume":"61","author":"Cantarini","year":"2015","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2017.02.008_bb0075","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2133.1990.tb01462.x","article-title":"Efficacy of intravenous immunoglobulins in sclerodermatomyositis","volume":"123","author":"Bodemer","year":"1990","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0080","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s100670050158","article-title":"Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin\u2014a preliminary report","volume":"19","author":"Levy","year":"2000","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0085","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/ard.62.2.175","article-title":"Fibrosis regression induced by intravenous gammaglobulin treatment","volume":"62","author":"Amital","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.02.008_bb0090","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/art.20195","article-title":"Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study","volume":"50","author":"Levy","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.02.008_bb0095","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/rheumatology\/keh600","article-title":"A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion","volume":"44","author":"Asano","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2017.02.008_bb0100","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1196\/annals.1361.121","article-title":"Response of vasculitic peripheral neuropathy to intravenous immunoglobulin","volume":"1051","author":"Levy","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2017.02.008_bb0105","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1365-2133.2007.07777.x","article-title":"High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma","volume":"156","author":"Ihn","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0110","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/ard.2006.060111","article-title":"Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study","volume":"66","author":"Nacci","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.02.008_bb0115","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archderm.144.5.585","article-title":"Response of dystrophic calcification to intravenous immunoglobulin","volume":"144","author":"Schanz","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10067-008-1062-2","article-title":"Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12months: follow-up of immunopathological and clinical effects","volume":"28","author":"Szekanecz","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12016-011-8278-7","article-title":"Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases","volume":"42","author":"Zandman-Goddard","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0130","first-page":"151","article-title":"A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis","volume":"31","author":"Takehara","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0135","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3109\/03009742.2013.868510","article-title":"Improvement in lung fibrosis using intravenous immunoglobulin in systemic sclerosis with myositis","volume":"43","author":"Mauhin","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0140","first-page":"176","article-title":"Benefit of intravenous immunoglobulin in a patient with longstanding polymyositis\/systemic sclerosis overlap syndrome","volume":"40","author":"Abelha-Aleixo","year":"2015","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.autrev.2017.02.008_bb0145","first-page":"S168","article-title":"Intravenous immunogobulin therapy for severe gastrointestinal involvement in systemic sclerosis","volume":"33","author":"Clark","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0150","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3899\/jrheum.140833","article-title":"Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis","volume":"42","author":"Poelman","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0155","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/rheumatology\/kev318","article-title":"Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis","volume":"55","author":"Raja","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.02.008_bb0160","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.02.008_bb0165","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0170","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2017.02.008_bb0175","series-title":"Aids to the examination of the peripheral nervous system","year":"1981"},{"issue":"Suppl. 4","key":"10.1016\/j.autrev.2017.02.008_bb0180","doi-asserted-by":"crossref","first-page":"S256","DOI":"10.1007\/s10072-003-0090-6","article-title":"High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials","volume":"24","author":"Dalakas","year":"2003","journal-title":"Neurol Sci"},{"key":"10.1016\/j.autrev.2017.02.008_bb0185","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/annrheumdis-2014-205226","article-title":"Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database","volume":"74","author":"Maurer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.02.008_bb0190","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/crj.12281","article-title":"An exploratory trial of intravenous immunoglobulin therapy for idiopathic pulmonary fibrosis: a preliminary multicenter report","volume":"10","author":"Enomoto","year":"2016","journal-title":"Clin Respir J"},{"key":"10.1016\/j.autrev.2017.02.008_bb0195","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/acr.21716","article-title":"Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group","volume":"64","author":"Muangchan","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2017.02.008_bb0200","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/art.10363","article-title":"The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice","volume":"46","author":"Blank","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.02.008_bb0205","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2249.2010.04295.x","article-title":"Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma","volume":"163","author":"Kajii","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2012.09.010","article-title":"Intravenous immunoglobulin treatment recovers the down-regulated levels of Th1 cytokines in the sera and skin of scleroderma patients","volume":"69","author":"Kudo","year":"2013","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.autrev.2017.02.008_bb0215","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1053\/j.gastro.2012.07.109","article-title":"Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function","volume":"143","author":"Singh","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2017.02.008_bb0220","doi-asserted-by":"crossref","first-page":"G1052","DOI":"10.1152\/ajpgi.00034.2016","article-title":"Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG","volume":"310","author":"Kumar","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.autrev.2017.02.008_bb0225","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/art.10361","article-title":"Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis","volume":"46","author":"Chizzolini","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.02.008_bb0230","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/art.38627","article-title":"Intravenous immunoglobulin attenuates experimental autoimmune arthritis by inducing reciprocal regulation of Th17 and Treg cells in an interleukin-10-dependent manner","volume":"66","author":"Lee","year":"2014","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2017.02.008_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031357","article-title":"Intravenous immunoglobulin prevents murine antibody-mediated acute lung injury at the level of neutrophil reactive oxygen species (ROS) production","volume":"7","author":"Semple","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2017.02.008_bb0240","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1002\/art.34534","article-title":"Reactive oxygen species\u2013mediated killing of activated fibroblasts by arsenic trioxide ameliorates fibrosis in a murine model of systemic sclerosis","volume":"64","author":"Kavian","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.02.008_bb0245","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis","volume":"354","author":"Baroni","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217300484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217300484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T09:57:04Z","timestamp":1536055024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997217300484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1568997217300484"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2017.02.008","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2017.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}